A practical reference on DAC linker: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-07. Anything still debated is marked as such rather than presented as settled.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
A number of people, starting with Gerald Kulcinski in 1986, have proposed to explore the Moon, mine lunar regolith, and use the helium-3 for fusion. Liquid helium-4 can be cooled to about 1 K (−272.15 °C; −457.87 °F) using evaporative cooling in a 1-K pot. Similar cooling of helium-3, which has a lower boiling point, can achieve about 0.2 kelvin in a helium-3 refrigerator. Equal mixtures of liquid 3He and 4He below 0.8 K separate into two immiscible phases due to their dissimilarity (they follow different quantum statistics: helium-4 atoms are bosons while helium-3 atoms are fermions). Dilution refrigerators use this immiscibility to achieve temperatures of a few millikelvins. It is possible to produce exotic helium isotopes, which rapidly decay into other substances. The shortest-lived heavy helium isotope is the unbound helium-10 with a half-life of 2.6(4)×10−22 s. Helium-6 decays by emitting a beta particle and has a half-life of 0.8 seconds. Helium-7 and helium-8 are created in certain nuclear reactions. Helium-6 and helium-8 are known to exhibit a nuclear halo.
== Anti-nRNP antibody == Anti-nuclear Ribonucleoprotein (Anti-nRNP) antibodies are a type of autoantibody, which are antibodies that wrongly target and attack a person's own cells, proteins or tissues. In particular, anti-nRNPs are directed against nuclear ribonucleoproteins (nRNPs), which are complexes composed of proteins and nucleic acids. These ribonucleoproteins play a critical role in various cellular processes, including RNA processing and gene expression. Anti-U1 RNP antibodies target proteins that are part of the U1 small nuclear ribonucleoprotein (U1-snRNP) complex. This complex is involved in RNA splicing, a process that removes non-coding regions from pre-messenger RNA before it is translated into proteins. Because RNA splicing is necessary for normal cell function, problems involving the U1-snRNP complex are associated with several autoimmune connective tissue diseases. Although researchers do not understand why anti-U1 RNP antibodies develop, studies suggest that both genetic and environmental factors contribute to the loss of immune tolerance that allows these antibodies to form.
Methamphetamine is a central nervous system (CNS) stimulant that is primarily used as a recreational or performance-enhancing drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder (ADHD). It has also been researched as a potential treatment for traumatic brain injury. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine. Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving its potential for misuse as an aphrodisiac and euphoriant, among other concerns, as well as the availability of other drugs with comparable effects and treatment efficacy such as dextroamphetamine and lisdexamfetamine. While pharmaceutical formulations of methamphetamine in the United States are labeled as methamphetamine hydrochloride, they contain dextromethamphetamine as the active ingredient. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine. Both racemic methamphetamine and dextromethamphetamine are illicitly trafficked and sold owing to their potential for recreational use and ease of manufacture.
15 May to 14 August The 1st Brigade, 101st Airborne Division conducted Operation Lamar Plain in Quảng Tín Province. The operation resulted in 524 PAVN/VC killed and 21 captured and U.S. losses were 116 killed and one missing.
== Availability == There are two types of isobaric tags commercially available: tandem mass tags (TMT) and isobaric tags for relative and absolute quantitation (iTRAQ). Amine-reactive TMT are available in duplex, 6-plex 10-plex, and now 11-plex sets. Amine-reactive iTRAQ are available in 4-plex and 8-plex forms.
Sources: en.wikipedia.org
Aldosterone is a mineralocorticoid which is synthesized in the adrenal glands. When aldosterone is secreted from the adrenal glands, it binds to the mineralocorticoid receptor in the renal tubule cell and forms a complex. This complex enhances transcription of specific DNA segments in the nucleus, leading to the formation of two protein transporters, Na+/K+ ATPase pump at the basolateral membrane and Na+ channel called ENaC, located at the apical membrane of the renal tubule cell. These protein transporters increase sodium reabsorption and potassium excretion in the distal tubule and the collecting duct of the kidneys. This helps the body to maintain normal volume and electrolyte balance, increasing the blood pressure. Mineralocorticoid receptor antagonists decrease the aldosterone effect by binding to the mineralocorticoid receptor inhibiting aldosterone. This leads to higher levels of potassium in serum and increased sodium excretion, resulting in decreased body fluid and lower blood pressure.
20 February Reg Douglas, Olympic rower (1956), British Empire and Commonwealth Games gold (1954, 1958) and silver medallist (1954) (born 1930). Sir Peter Trapski, lawyer and judge, chief District Court judge (1985–1989) (born 1935). Maata Wharehoka, weaver, Māori arts advocate, community leader (Parihaka), Ngā Tohu ā Tā Kīngi Īhaka (2015) (born 1950). 21 February – John Anderson, businessman, founder of Contiki Tours (1962) (born 1938). 24 February – Khalid Sandhu, Muslim community leader and physician, president of the Federation of Islamic Associations of New Zealand (1986–1988, 1989–1990) (born 1942). 27 February Dave Gillespie, rugby union player (Otago, Wellington, national team) (born 1934). Michael Moroney, Hall of Fame Thoroughbred racehorse trainer (Brew, Tofane, Xcellent) (born 1958).
== SPE and chromatography == SPE is in fact a method of chromatography, in the sense of having a mobile phase, carrying mixtures through a stationary phase, packed inside a column. The chromatographic process is harnessed to create a solid-liquid extractive technique—allowing separation of a mixture of components by taking advantage of large differences between the solid and liquid phase Keq, or equilibrium constant, for each component in the mixture. The chemical considerations for the selection of stationary and mobile phases are similar to those for liquid column chromatography and many of the adsorbents/materials used are the same. The theory, procedures, and aims are different, however, and as an extractive technique it has a unique niche in modern chemical science.
Radioactive thorium was used in the 1950s and 60s to treat tuberculosis and other benign diseases (including children), with serious consequences (see Peteosthor). A stabilized suspension of colloidal thorium(IV) oxide, co-developed by António Egas Moniz (1874-1954), was used from 1929 under the trade name Thorotrast as an X-ray contrast agent for angiography in several million patients worldwide until it was banned in the mid-1950s. It accumulates in the reticulohistiocytic system and can lead to cancer due to locally increased radiation exposure. The same is true for cholangiocarcinoma and angiosarcoma of the liver, two rare liver cancers. Carcinomas of the paranasal sinuses have also been described following administration of Thorotrast. Typical onset of disease is 30–35 years after exposure. The biological half-life of Thorotrast is approximately 400 years. The largest study in this area was conducted in Germany in 2004 and showed a particularly high mortality rate among patients exposed in this way. The median life expectancy over a seventy-year observation period was 14 years shorter than in the comparison group.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.